louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04100616: A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Obesity
Official title: A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Obesity
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Overweight and Obesity
Overweight or Obesity
Obesity
Obesity, Morbid
Obesity, Abdominal
Obesity; Familial
Obesity; Endocrine
Obesity, Visceral
Obesity Hypoventilation Syndrome
Lead sponsor: ProgenaBiome
Sponsor class: OTHER
First posted: 2019-09-24
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adults 18 years of age and older with a BMI greater than or equal to 30

Brief summary: This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding obesity.

Detailed description: The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to the information provided in surveys and in medical records, particularly regarding obesity.

Eligibility criteria: Inclusion Criteria:

1. Signed informed consent by patient
2. Male or female patients age 18 and older.
3. Diagnosis of obesity based on Body Mass Index (BMI) of 30 or greater.

Exclusion Criteria:

1. Refusal by patient to sign informed consent form
2. Treatment with antibiotics within two weeks prior to screening
3. Treatment with probiotics within six weeks prior to screening
4. History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy
5. Postoperative stoma, ostomy, or ileoanal pouch
6. Participation in any experimental drug protocol within the past 12 weeks
7. Treatment with total parenteral nutrition
8. Any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial
9. Inability of patient to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study

Primary outcomes:
measure: Correlation of Microbiome to Obesity via Relative Abundance Found in Microbiome Sequencing
timeFrame: 1 year
Secondary outcomes:
measure: Validation of Sequencing Methods
timeFrame: 1 year
Other outcomes:
Locations:
city: Ventura
country: United States
facility: ProgenaBiome
state: California
Study officials:
affiliation: ProgenaBiome
name: Sabine Hazan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06926816: Universal Genetic Testing for Cancer Risk Reduction
Official title: Universal Genetic Testing for Cancer Risk Reduction
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Genetic Testing
Keywords: Cancer
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2025-04-15
Enrollment: 600
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The purpose of this research study is to see if offering genetic testing for cancer-related genes is feasible and acceptable for patients presenting for gynecology clinic visits, instead of needing to see specialized providers or needing to meet specific criteria. The primary aim to assess the proportion of patients who undergo genetic testing, and the proportion of patients with pathogenic variants.


Eligibility criteria: Inclusion Criteria:

1. Female patients between ages of 25-39 years at the time of visit
2. Receive gynecologic care at an affiliated NYU Langone Health (NYULH) site listed in this protocol.

Exclusion Criteria:

1. Personal history of ovarian, fallopian tube, primary peritoneal, or uterine cancers
2. Previously undergone germline testing for ovarian cancer risk variants (prior commercial saliva-based kits, such as 23andMe, are acceptable)
3. History of bilateral salpingo-oophorectomy
4. Visit related to pregnancy or immediately postpartum (within 2 weeks)

Primary outcomes:
measure: Number of participants who undergo genetic testing
timeFrame: Up to 9 months
Secondary outcomes:
measure: Number of participants with pathogenic variants
timeFrame: Up to 9 months
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Langone Health
state: New York
Study officials:
affiliation: NYU Langone Health
name: Bhavana Pothuri, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03684616: Epidemiology, Management, Prognosis and Medical Cost Analysis of IHCA and OHCA
Official title: Epidemiology, Management, Prognosis and Medical Cost Analysis of In-hospital and Out-of-hospital Cardiac Arrest Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Out-Of-Hospital Cardiac Arrest
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2018-09-26
Enrollment: 100000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The out-of-hospital cardiac arrest patients from 2004-2012 were included for analysis

Brief summary: The study is a retrospective analysis of Taiwan national health insurance in cardiac arrest patients. The factors related to the outcomes of cardiac arrest patients were analyzed.


Eligibility criteria: Inclusion Criteria:

* out-of-hospital cardiac arrest,

Exclusion Criteria:

-

Primary outcomes:
measure: one year survival
timeFrame: up to one year
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
References:
Clinical trial NCT05205824: Validation IMU and EMG Algorithms in Stroke Patients
Official title: Validation IMU and EMG Algorithms in Stroke Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Lead sponsor: Roessingh Research and Development
Sponsor class: OTHER
First posted: 2022-01-25
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The objective is to validate the algorithms for movement analysis that were developed previously in healthy participants, in a small study with stroke patients. Stroke subjects will be measured while performing tasks like walking, sitting and standing while wearing light-weight inertial measurements units (IMUs) incorporating 3D accelerometers, 3D gyroscopes and surface electromyography. During the measurements subjects will be recorded on video that serves as ground truth when validating the implemented algorithms for movement analysis. A face blurring program will be used for all video footage.

Detailed description: Subjects will perform the following tasks: 30 sec stationary sitting/standing/lying; 10m walk test; L-test; 8-figure walking test; daily life task; stepping over small obstacles; walk in the corridor. During the measurments IMU will be placed at: sternum; sacrum; bilateral wrists; bilateral shanks; bilateral upper legs; both feet. Surface EMG of bilateral rectus femoris; vastus lateralis; medial gastrocnemius and soleus will be measured.

Eligibility criteria: Inclusion Criteria:

* min 18 yrs of age; history of previous stroke; unilateral affected;able to walk without supervision (FAC-score min 4);able to perform activities of daily living without assistance (self-reported); written informed consent.

Exclusion Criteria:

* subjects with neurological or motor disorders that could interfere with the measurements (other than stroke) or severe deficits in communication, memory and understanding.

Primary outcomes:
measure: Inertial measurement unit data
timeFrame: 1-2 hours
Secondary outcomes:
measure: surface EMG-data
timeFrame: 1-2 hours
Other outcomes:
measure: anonymized video data
timeFrame: 1-2 hours
measure: Age
timeFrame: at inclusion
measure: Height
timeFrame: at inclusion
measure: Leg length
timeFrame: at inclusion
measure: Time since stroke
timeFrame: at inclusion
measure: Type of stroke
timeFrame: at inclusion
measure: Body side
timeFrame: at inclusion
measure: FAC-score
timeFrame: at inclusion
measure: Motricity Index
timeFrame: at inclusion
Locations:
city: Enschede
country: Netherlands
facility: Roessingh Research and Development
Study officials:
affiliation: Roessingh Research and Development
name: C Nikamp, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04031924: Kinesiophobia and Physical Fitness, and Related Factors in Liver Transplantation
Official title: An Evaluation of Balance, Functional Capacity, Kinesiophobia and Physical Fitness in Patients With Liver Transplantation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Liver Transplant Disorder
Keywords: liver transplantation
functional capacity
kinesiophobia
balance
physical fitness
physical activity
muscle strength
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2019-07-24
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Sixteen individuals older than 18 years of age who had undergone liver transplantation at Hacettepe University Hospital at least one year ago and 16 age- and sex-matched healthy subjects were included in the study

Brief summary: Kinesiophobia and Physical Fitness, and Related Factors in Liver Transplantation


Eligibility criteria: Inclusion Criteria:

* All patients older than 18 years of age who had undergone liver transplantation at Hacettepe University Hospital at least one year ago were eligible for the study.

Exclusion Criteria:

* Hepatic encephalopathy
* Progressive cardiac and/or pulmonary disease
* Central nervous system pathologies
* Orthopedic problems preventing physical assessments
* Multiorgan transplantation
* Cognitive deficits

Primary outcomes:
measure: Physical Fitness
timeFrame: 10 minutes
measure: Physical Fitness
timeFrame: 10 minutes
measure: Physical Fitness
timeFrame: 30 minutes
measure: Physical Fitness
timeFrame: 5 minutes
measure: Physical Fitness
timeFrame: 5 minutes
measure: Physical Fitness
timeFrame: 10 minutes
Secondary outcomes:
measure: Kinesiophobia
timeFrame: 15 minutes
measure: Balance
timeFrame: 20 minutes
measure: Balance
timeFrame: 15 minutes
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacettepe University
Study officials:
References:
Clinical trial NCT01069796: Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
Official title: A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel and Capecitabine in First Line Treatment for Patients With Triple Negative Metastatic or Locally Advanced Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Triple Negative Metastatic Breast Cancer
Keywords: triple negative
metastatic
breast cancer
First line chemotherapy
Lead sponsor: ARCAGY/ GINECO GROUP
Sponsor class: OTHER
First posted: 2010-02-17
Enrollment: 64
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).


Eligibility criteria: Inclusion Criteria:

* Female histologically confirmed adenocarcinoma of the breast ER-, PR-, HER2- disease
* Measurable disease
* Patients may received prior radiotherapy as adjuvant treatment or/and metastatic disease provided that they have progressive disease at study entry

Exclusion Criteria:

* Prior chemotherapy for metastatic disease
* HER2 positive and/or hormonal receptor positive

Primary outcomes:
measure: objective response rate
timeFrame: 36 months for recrutment and 30 months for follow up
Secondary outcomes:
Other outcomes:
Locations:
city: Angers
country: France
facility: Centre Paul Papin
city: Bordeaux
country: France
facility: Clinique Tivoli
city: Chalon sur Saône
country: France
facility: Centre Hospitalier William Morey
city: Fréjus
country: France
facility: Centre Hospitalier Intercommunal
city: Lormont
country: France
facility: Clinique des 4 Pavillons
city: Marseille
country: France
facility: Hôpital Privé Clairval
city: Mougins
country: France
facility: Centre Azuréen de Cancérologie
city: Nancy
country: France
facility: Centre Alexis Vautrin
city: Nice
country: France
facility: Centre Antoine Lacassagne
city: Orléans
country: France
facility: Centre Hospitalier Régional
city: Reims
country: France
facility: Institut Jean Godinot
city: Romans sur Isère
country: France
facility: Hôpitaux Drôme Nord - Site de Romans-sur-Isère
city: Rouen
country: France
facility: Centre Henri Becquerel
city: Saint Brieuc
country: France
facility: Clinique Armoricaine de Radiologie
city: St Jean
country: France
facility: Clinique de l'Union
city: Strasbourg
country: France
facility: Centre Paul Strauss
city: Vannes
country: France
facility: Centre Hospitalier Bretagne Atlantique
Study officials:
References:
Clinical trial NCT06430996: Caffeinated Chewing Gum on 400-meter Performance
Official title: Effects of Caffeinated Chewing Gum on 400-meter Performance and Fatigue Index of Sprinters: a Crossover Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Caffeine
Placebo
Keywords: exercise performance
fatigue index
α amylase
Lead sponsor: National Taiwan Sport University
Sponsor class: OTHER
Collaborators: name: National Science and Technology Council
First posted: 2024-05-28
Enrollment: 19
Sex: MALE
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: 20 trained sprinter were divided into caffeine Gum trial (CAF) and Placebo trial (PL) with a randomized, double-blind study design. The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. The outcomes are Running-Based Anaerobic Sprint Test and 400-meter sprint test was performed.

Detailed description: The purpose of this study was to investigate the effect of caffeinated chewing gum on 400-meter sprint performance. 20 trained sprinter were divided into caffeine Gum trial (CAF) and Placebo trial (PL) with a randomized, double-blind study design. The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. After rested for 15 minutes, the participants underwent a Running-Based Anaerobic Sprint Test. After a 30-minute break, a 400-meter sprint test was performed. The blood lactate concentration were collected before and after 400-meter sprint from finger. Saliva samples were predicted to be collected before chewing gum, before the RAST, and after a 400-meter sprint. Saliva samples will be analyzed for caffeine and α-amylase concentrations in saliva.

Eligibility criteria: Inclusion Criteria:

* 6 years of professional short sprinting training
* 6 months of ongoing training, and
* 3 months of recovery from sports injuries such as strains and sprains.

Exclusion Criteria:

* Non-specialized sprinters.
* has not trained regularly for the past 6 months.
* has recovered from an athletic injury.
* less than 3 months of recovery from a sports injury, or participants with epilepsy, hypertension, hyperlipidemia, heart disease, arthritis, osteoporosis, brain injury, or a history of caffeine allergy.

Primary outcomes:
measure: Running-Based Anaerobic Sprint Test (RAST)
timeFrame: 15 minutes after intervention
measure: 400-meter sprinting
timeFrame: 30 minutes after RAST
Secondary outcomes:
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: National Taiwan University of Sport
Study officials:
affiliation: Sport Science Research Center
name: ChihHui Chiu, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05186896: NETTUNIT - Italy-Tunisia Cross-border Environmental network_2
Official title: NETTUNIT - Italy-Tunisia Cross-border Environmental network_2
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Risk Perception
Lead sponsor: Istituto per la Ricerca e l'Innovazione Biomedica
Sponsor class: OTHER
First posted: 2022-01-11
Enrollment: 1000
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Individuals aged 20-90 years of both sex, living in the areas of Caltanissetta (Italy) and Tunis (Tunisia).

Brief summary: The study involves the development and validation of a questionnaire for risk perception to be administered to residents of areas declared to be at high risk of environmental crisis in the areas of Caltanissetta (Italy) and Tunis (Tunisia). The questionnaire will be administered twice, at baseline and after 1 month.


Eligibility criteria: Inclusion Criteria:

* Individuals aged 20-90 years of both sex, living in the areas of Caltanissetta (Italy) and Tunis (Tunisia).

Exclusion Criteria:

* Individuals with learning difficulties.

Primary outcomes:
measure: Construct validity of the questionnaire score at baseline administration
timeFrame: Baseline administration
measure: Construct validity of the questionnaire score 1 month after the baseline administration
timeFrame: 1 month after the baseline administration
measure: Repeatability of the questionnaire score between the first (baseline) and second (1 month) administration
timeFrame: Baseline administration and 1 month after the baseline administration
Secondary outcomes:
Other outcomes:
Locations:
city: Palermo
country: Italy
facility: Institute for Biomedical Research and Innovation (IRIB) - National Research Council (CNR)
Study officials:
References:
Clinical trial NCT06472596: Risk of Chronic Kidney Disease in Bronchial Asthma
Official title: Risk of Developing Chronic Kidney Disease in Patients With Bronchial Asthma at Sohag University Hospitals
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Bronchial Asthma
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-06-25
Enrollment: 100
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: cases (asthmatics) and control ( healthy ) from age of 2 years to 18 years

Brief summary: the study aims to determine the frequency and factors associated with chronic kidney disease among asthmatic patients in order to determine persons who are at risk of developing chronic kidney disease and require strict follow up in long run , to evaluate severity of asthma as a potential risk for developing kidney injury , to evaluate relationship between different inflammatory markers with severity of asthma and risk of deneloping chronic kidney disease


Eligibility criteria: Inclusion Criteria:

* all children diagnosed as bronchial asthma at sohag university hospitals from age of 2 years to age of 18 years and donot have any associated disease

Exclusion Criteria:

* persons who have any chronic illness persons who have any associated disease with bronchial asthma persons who missing clinical and laboratory investigations persons who refusing to give written informed consent for the study

Primary outcomes:
measure: change in kidney function in asthmatics
timeFrame: change in kidney function in asthmatics after diagnosis and start treatment through out the duration of study (an average 1 year )
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Marihan Nazmy Shehata
Study officials:
References:
Clinical trial NCT04497896: Playtime Open Globe Injuries in Children
Official title: Epidemiology, Aetiologies, and Complications of Playtime Open-globe Injuries in Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Eye Trauma
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-08-04
Enrollment: 81
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: all children (age ≤18 years) admitted to Assiut university hospital with open-globe injuries that occurred during playtime over a 6-month study period (January-July 2016).

Brief summary: This study investigated the epidemiology, aetiologies, and complications of playtime open-globe injuries in children at the Assiut University Hospital, Egypt, between January to July 2016.

Detailed description: This prospective study was conducted at the Department of Ophthalmology, Assiut University Hospital, which is the largest tertiary referral hospital in Upper Egypt and provides 24-hour ophthalmic emergency services for six governorates. The study included all children (age ≤18 years) admitted with open-globe injuries that occurred during playtime over a 6-month study period. Demographic information (age and sex), the site and mechanism of injury, the site of ocular laceration (corneal, scleral or corneoscleral) and associated complications were recorded and analysed.

Eligibility criteria: Inclusion Criteria:

* all children (age ≤18 years) admitted with open-globe injuries that occurred during playtime over a 6-month study period (January-July 2016).

Exclusion Criteria:

* Open globe injuries in patients olader than 18 years.
* Closed globe injuries

Primary outcomes:
measure: Visual acuity (in Decimal using Snellen chart) after repair of open globe injury
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: